

ASX ANNOUNCEMENT

KEY MIDKINE ANTIBODY PATENTS GRANTED IN THE US AND EUROPE

- **Key US and European patents granted for Cellmid's midkine (MK) antibodies**
- **Significant commercial value - the patents are important for partnering**
- **The patents secure comprehensive protection over midkine antibodies to treat cancer, inflammatory diseases and auto-immune disorders**

SYDNEY, Monday, 6 January 2020: Cellmid Limited (ASX: CDY) is pleased to advise that it has received notice of allowance for the *Improved midkine antibody* patent from the USPTO (Application No. 15/518,849). In addition, and following a 'Notification of Intention to Grant' from the European Patent Office (ASX announcement 22 August 2019) for the *Improved midkine antibody* patent (Application No. 15849875.8), the EPO has now issued a 'Decision to Grant'.

Significant commercial value

The simultaneous granting of these patents in the US and key European territories (expiry 14/10/2035) represents a major milestone in the midkine therapeutic program. The humanised therapeutic antibody covered by the US and European patents is one of the lead drugs in the midkine program and adds significant commercial value to the comprehensive intellectual property portfolio around midkine.

Protection for the humanized midkine antibodies

This patent family protects the composition of humanised antibodies that recognize regions within the C-domain of the midkine protein. The patent family also protects the use of these humanised midkine antibodies in several disease settings including the diagnosis and treatment of cancer, inflammatory diseases and autoimmune conditions such as multiple sclerosis.

Patents add to Cellmid's dominant intellectual property position in midkine globally

The newly granted midkine antibody patents and allied patent families underpin the Company's dominant intellectual property position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer, chronic inflammation, as well as functional disorders in T-regulatory cells and activated neutrophils associated with autoimmune diseases.

Cellmid's total midkine patent portfolio currently comprises 67 patents and applications in 12 patent families, including patents covering the use of midkine and anti-MK agents for therapeutic purposes in a number of diseases such as cancer, inflammatory conditions and autoimmune diseases.

Approved for release by the Board of Directors.

CONTACT:

Maria Halasz, CEO
T +612 9221 6830



@mariahalasz



Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and antiaging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Cellmid's wholly owned subsidiary, Lynamid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Lynamid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally. For further information see www.lyramid.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, technical hurdles, the results of marketing and sales activities and competition.